Additionally, VSIG4+ TAMs may contribute to the adverse prognosis through TAMs-mediated tumor immune mechanisms that are independent of CD8+ TILs regulation in DLBCL and may serve as a promising immune checkpoint target. This evidence concerns the gene CD8A and diffuse large B-cell lymphoma.